A record year for biopharma M&A in 2019

We saw lots of action in the biopharma merger and acquisition (M&A) space in 2019, headlined by Bristol-Myers Squibb acquiring Celgene for about $75 billion and AbbVie acquiring Allergan for $63 billion. With no signs of slowing down, what will we see in 2020?